PGEN Precigen (PGEN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001356090
Form 144 · 7
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
121
13F, latest reported quarter
Conversions, 180 days
20
Codes C/M, not in net · $1.4M priced
What the filings say about PGEN
Insiders, 180 days
-$7.9M net sold
1 buyer · 6 sellers · 19% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.4M
7 notices
Precigen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PRECIGEN, INC. insiders sold a net $7.9M of stock across 143 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Dec 12, 2025.
- The trade is 1081.9% of the 17,100 shares held after it.
- 3 other insiders sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KINDLER JEFFREY B sold about $1.4M of PGEN on Aug 26, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on May 28, 2026.
- The trade is 55.8% of the 141,992 shares held after it.
- 3 other insiders sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Tennant Phil sold about $593.7K of PGEN under a 10b5-1 plan on Aug 25, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (2 buys, 9 sales), the last on Aug 21, 2026.
- -5.1% median (-5.1% mean) 90-day return after 2 previous buys.
- The trade is 3.3% of the 468,865 shares held after it.
- 3 other insiders sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Shah Rutul R sold about $115.1K of PGEN under a 10b5-1 plan on Aug 25, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (2 buys, 8 sales), the last on Aug 6, 2026.
- -5.1% median (-5.1% mean) 90-day return after 2 previous buys.
- The trade is 7.5% of the 465,012 shares held after it.
- 3 other insiders sold within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Shah Rutul R sold about $259.9K of PGEN under a 10b5-1 plan on Aug 21, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 4, 2025.
- -17.8% median (+4.2% mean) 90-day return after 3 previous buys.
- The trade is 1.1% of the 309,187 shares held after it.
- No other insider bought within 30 days.
- 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AGEE NANCY H bought about $24.7K of PGEN on Aug 21, 2026; 121 funds added in the latest 13F quarter.143 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$7.9M over 180 days
-$3.4M over 90 days
below 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
121 funds bought in last quarter
more than 76% of Pharma & Biotech
Revenue
+146.7% year over year
more than 87% of Pharma & Biotech
Margin
-2588.2% net margin
below 94% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.8% of the float short (float per yahoo 2026-10-27) · 10.2 days to cover · settled 2026-10-15
more than 81% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PGEN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+42.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PGEN: institutional holders (13F)
13F holdings, latest reported quarter
19,036,976 sh
$108.5M
17,146,921 sh
$97.7M
12,002,465 sh
$68.4M
9,269,926 sh
$52.8M
7,906,160 sh
$45.1M
Congress trades in PGEN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PGEN planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Jeffrey Kindler
Filed 2026-08-26
$1.4M
Tennant Phil
Filed 2026-08-25
$593.7K
Shah Rutul R
Filed 2026-08-25
$115.1K
Shah Rutul R
Filed 2026-08-21
$259.9K
Shah Rutul R
Filed 2026-08-06
$224.6K
PGEN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Patient Opportunity Trust
$73.5M position · as of 2026-06-30
3.7%
Virtus Biotech Etf
$1.9M position · as of 2026-07-31
1.9%
Putnam VT Small Cap Value Fund
$1.4M position · as of 2026-06-30
1.1%
Putnam Small Cap Value Fund
$3.0M position · as of 2026-05-31
1.0%
1290 Essex Small Cap Growth Fund
$1.1M position · as of 2026-07-31
1.0%
First Trust Small Cap Growth AlphaDEX Fund
$9.7M position · as of 2026-07-31
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
2 active
1
Phase 2
1 active
1
Phase 4
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Helen Sabzevari
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$3.5M
-$1.1M
$892.4K
-72%
+14%
2021
$2.5M
-$16.1M
$611.0K
-32%
+26%
2020
$20.4M
$41.5M
$1.2M
+86%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.9M sold by insiders over 180 days, 121 funds added last quarter, $3.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PGEN financials
Revenue growth
+146.7%
XBRL, annual
Net margin
-2588.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | $103.9M |
| Jun 2026 | $55.0M |
| Mar 2026 | $23.3M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $856.0K |
| Mar 2025 | $1.3M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -88.8% |
| Jun 2026 | +36.5% |
| Mar 2026 | -34.1% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -3,112% |
| Mar 2025 | -4,038% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$115.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PGEN
| FY Dec 2025 | -$89.8M |
| FY Dec 2024 | -$76.8M |
| FY Dec 2023 | -$68.5M |
| FY Dec 2022 | -$70.0M |
| FY Dec 2021 | -$63.0M |
| Jun 2026 | -$18.2M |
| Mar 2026 | -$44.1M |
| Dec 2025 | -$23.5M |
| Sep 2025 | -$29.5M |
| Jun 2025 | -$19.9M |
| Mar 2025 | -$16.9M |
| Dec 2024 | -$9.3M |
| Sep 2024 | -$23.6M |
At each fiscal year end
Single quarter
Debt to equity
2.15x
long-term 2026-06-30 plus current 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity PGEN
| FY Dec 2025 | 4.46x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.34x |
| FY Dec 2021 | 1.68x |
| Jun 2026 | 2.15x |
| Mar 2026 | 4.62x |
| Dec 2025 | 4.46x |
| Sep 2025 | 2.22x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.22x
TTM operating cash flow over long-term 2026-06-30 plus current 2023-12-31 (30 months older than the period end)
Cash flow to debt PGEN
| FY Dec 2025 | -0.94x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.51x |
| FY Dec 2021 | -0.31x |
| Jun 2026 | -1.22x |
| Mar 2026 | -1.23x |
| Dec 2025 | -0.94x |
| Sep 2025 | -0.78x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-4,639%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PGEN
| FY Dec 2025 | -843.4% |
| FY Dec 2024 | -160.8% |
| FY Dec 2023 | -78.4% |
| FY Dec 2022 | +24.2% |
| FY Dec 2021 | -105.7% |
| Jun 2026 | -4,639% |
| Mar 2026 | -6,619% |
| Dec 2025 | -843.4% |
| Sep 2025 | -507.7% |
| Jun 2025 | -3,895% |
| Mar 2025 | -377.6% |
| Dec 2024 | -160.8% |
| Sep 2024 | -137.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-115.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PGEN
| FY Dec 2025 | -166.6% |
| FY Dec 2024 | -85.2% |
| FY Dec 2023 | -52.3% |
| FY Dec 2022 | +9.8% |
| FY Dec 2021 | -27.3% |
| Jun 2026 | -115.8% |
| Mar 2026 | -152.9% |
| Dec 2025 | -166.6% |
| Sep 2025 | -193.8% |
| Jun 2025 | -142.2% |
| Mar 2025 | -118.8% |
| Dec 2024 | -85.2% |
| Sep 2024 | -101.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | -68.8% |
| FY Dec 2023 | -65.3% |
| FY Dec 2022 | -37.4% |
| FY Dec 2021 | -29.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -68.8% |
| Sep 2024 | -78.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 10.86x |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.2B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value PGEN
| FY Dec 2025 | $1.5B |
| FY Dec 2024 | $298.5M |
| FY Dec 2023 | $326.0M |
| FY Dec 2022 | $354.7M |
| FY Dec 2021 | $910.5M |
| Jun 2026 | $2.1B |
| Mar 2026 | $1.5B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.1B |
| Jun 2025 | $405.4M |
| Mar 2025 | $432.1M |
| Dec 2024 | $298.5M |
| Sep 2024 | $215.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield PGEN
| FY Dec 2025 | -6.1% |
| FY Dec 2024 | -23.4% |
| FY Dec 2023 | -20.5% |
| FY Dec 2022 | -22.1% |
| FY Dec 2021 | -8.2% |
| Jun 2026 | -5.7% |
| Mar 2026 | -8.5% |
| Dec 2025 | -6.1% |
| Sep 2025 | -7.7% |
| Jun 2025 | -16.6% |
| Mar 2025 | -17.2% |
| Dec 2024 | -23.4% |
| Sep 2024 | -35.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing PGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M |
| Operating income | -$110.5M | -$135.0M | -$99.8M | n/a |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M |
| EPS (diluted) | -1.37 | -0.47 | -0.39 | 0.14 |
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M |
| Cash | $30.2M | $29.5M | $7.6M | $4.9M |
| Long-term debt | $93.2M | $0 | n/a | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
PGEN Stock Sonar score 6/7 axes
Find similar shapesComparePGEN ranks highest on growth (87th percentile) and institutional and government (76th), and lowest on profitability (11th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PGEN filings, in plain words
Are Precigen insiders buying or selling PGEN?
In the 180 days to 2026-10-28, Precigen insiders were net sellers, a net $7.9M: $24.7K of purchases and $8.0M of sales reported on Form 4, by 1 buyer and 6 sellers.
Are there planned insider sales of PGEN?
Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $3.4M of stock; the latest, by Jeffrey Kindler, was filed 2026-08-26.
Read the full summary
In the 180 days to 2026-10-28, Precigen insiders were net sellers of PGEN, a net $7.9M across purchases and sales reported on Form 4 by 1 buyer and 6 sellers. Sales outweighed purchases more than tenfold by value. 19% of the 16 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $3.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
